Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVASTIN vs AMINOPHYLLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.
Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Metastatic colorectal cancer (first- or second-line in combination with intravenous 5-fluorouracil-based chemotherapy),Non-small cell lung cancer (first-line in combination with carboplatin and paclitaxel for unresectable, locally advanced, recurrent or metastatic non-squamous disease),Glioblastoma (single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (in combination with interferon alfa),Ovarian epithelial, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel and carboplatin or pegylated liposomal doxorubicin for platinum-sensitive recurrent disease; as a single agent for platinum-resistant recurrent disease),Cervical cancer (in combination with paclitaxel and cisplatin or topotecan for persistent, recurrent, or metastatic disease),Off-label uses: age-related macular degeneration (intravitreal), hereditary hemorrhagic telangiectasia, ovarian cancer (first-line maintenance), breast cancer (not FDA approved)
Treatment of acute bronchial asthma, reversible bronchospasm associated with chronic bronchitis and emphysema,Neonatal apnea (off-label),Adjunctive therapy in COPD exacerbations
5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
Terminal half-life approximately 20 days (range 11–50 days) in patients; supports dosing every 2–3 weeks
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Bevacizumab is primarily metabolized via proteolytic degradation into small peptides and amino acids. No specific metabolic enzymes are involved; it is not metabolized by cytochrome P450 enzymes.
Hepatic demethylation and oxidation via cytochrome P450 isoenzymes (CYP1A2, CYP3A4, CYP2E1); approximately 10% excreted unchanged in urine.
Primarily via reticuloendothelial system and proteolytic catabolism; negligible renal excretion (<1% unchanged in urine)
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Bound primarily to albumin and other plasma proteins; approximately 95–100% bound (saturable binding to Fc Rn may occur)
~40% bound to plasma proteins (primarily albumin).
Vd approximately 2.9–3.7 L (not weight-normalized; small Vd consistent with large monoclonal antibody confined mainly to plasma and interstitial space)
0.5 L/kg (range 0.3–0.7 L/kg); increased in neonates, cirrhosis, and malnutrition; reflects distribution into total body water.
Only available as intravenous infusion; bioavailability 100% by IV route; not administered subcutaneously or orally (no bioavailability data for other routes)
Oral (immediate-release): 100% (well absorbed); rectal: ~80% (variable); IV: 100%.
No dose adjustment is recommended for patients with renal impairment; however, be cautious in severe renal impairment (GFR <30 m L/min) due to limited data.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25% and monitor levels; GFR <10 m L/min: reduce dose by 50% and monitor levels closely.
No specific dose adjustment guidelines exist for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: use with extreme caution, reduce dose by 90% or consider alternative.
Safety and efficacy in pediatric patients have not been established; no standard dosing guidelines available.
Loading dose: 5-6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: infants <1 year: 0.4-0.7 mg/kg/hr IV; children 1-9 years: 0.8-1.0 mg/kg/hr IV; children >9 years: 0.6-0.8 mg/kg/hr IV. Oral: immediate-release 5 mg/kg every 6 hours; sustained-release not recommended under 6 years.
No specific dose adjustment is required for elderly patients; however, monitor for increased incidence of arterial thromboembolic events, hypertension, and proteinuria as seen in clinical trials.
Reduce maintenance dose by 50-75% compared to younger adults; monitor serum theophylline levels closely; typical starting maintenance: 0.3-0.5 mg/kg/hr IV; avoid doses >400 mg/day oral.
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE. Gastrointestinal perforations occur in up to 2.4% of patients. Discontinue for perforations, tracheoesophageal fistula, or wound dehiscence. Severe or fatal hemorrhage, including hemoptysis and gastrointestinal bleeding, has occurred; monitor for bleeding.
No specific FDA boxed warning for aminophylline; however, theophylline (its active metabolite) has a narrow therapeutic index and requires serum concentration monitoring to avoid toxicity.
Gastrointestinal perforations and fistulae (including tracheoesophageal),Surgery and wound healing complications: do not administer within 28 days of major surgery or until wound is fully healed,Hemorrhage: severe or fatal pulmonary hemorrhage (particularly in squamous NSCLC), gastrointestinal bleeding, and cerebral hemorrhage,Non-gastrointestinal fistula formation (including bronchopleural, biliary, and vaginal),Arterial thromboembolic events (e.g., stroke, myocardial infarction): risk increased in patients ≥65 years of age,Hypertension: monitor blood pressure; may require antihypertensive therapy,Reversible posterior leukoencephalopathy syndrome (RPLS),Proteinuria: monitor urine protein; discontinue if nephrotic syndrome develops,Ovarian failure: may impair fertility in women,Congestive heart failure: increased incidence in patients receiving anthracyclines or with prior chest radiation
Narrow therapeutic index; monitor serum concentrations (target 10-20 mcg/m L); caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, cardiac arrhythmias; use with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, fluvoxamine) or induce metabolism (e.g., smoking, rifampin, phenytoin).
Known hypersensitivity to bevacizumab or any components of the formulation,Recent hemoptysis (≥2.5 m L of red blood) within 21 days prior to treatment,Untreated central nervous system metastases (due to risk of bleeding; treat prior to bevacizumab)
Hypersensitivity to aminophylline, theophylline, or ethylenediamine; active peptic ulcer disease; uncontrolled seizure disorders; severe cardiac arrhythmias (unless patient is undergoing monitored treatment).
No specific food interactions known. No restrictions beyond general dietary advice for cancer patients.
High-fat meals can delay absorption of aminophylline. Avoid charred meat and foods containing large amounts of caffeine. Cruciferous vegetables (broccoli, brussels sprouts) may increase metabolism. Maintain consistent dietary intake of protein and carbohydrates as changes can affect theophylline clearance.
Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal impairment, and spontaneous abortion reported. Avoid use unless potential benefit justifies risk.
Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal asthma control benefits outweigh risks. Third trimester: Risk of neonatal apnea, irritability, and tachycardia if maternal levels are high; avoid toxic levels.
No data on excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during therapy and for at least 6 months after last dose.
Aminophylline is excreted into breast milk; the M/P ratio (milk-to-plasma ratio) is approximately 0.6-0.8. Infant exposure is low (about 1-10% of maternal weight-adjusted dose). Use with caution; monitor infant for irritability and sleep disturbance. Generally considered compatible with breastfeeding.
No formal dose adjustment studies in pregnancy. Increased volume of distribution and clearance may occur, but no dose changes recommended. Use lowest effective dose with careful monitoring.
Pregnancy reduces theophylline clearance by 30-50% due to decreased hepatic metabolism and increased volume of distribution. Dose adjustments may be needed: reduce dose by 30% in the third trimester or monitor serum concentrations closely to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; readjust accordingly.
Monitor blood pressure closely; hypertension is common. Hold therapy 28 days before elective surgery due to impaired wound healing. Use with caution in patients with cardiovascular disease or history of arterial thromboembolism. Proteinuria monitoring required; urine dipstick at baseline and regularly. Avoid in patients with recent hemoptysis or untreated CNS metastases.
Aminophylline is a bronchodilator composed of theophylline and ethylenediamine. The ethylenediamine component can cause hypersensitivity reactions. Monitor theophylline serum levels (target 10-20 mcg/m L). Use with caution in patients with cardiac arrhythmias, seizures, or peptic ulcer disease. Avoid in patients with porphyria. Cimetidine, ciprofloxacin, and macrolides can increase theophylline levels. Smoking induces metabolism, requiring higher doses.
Report any signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine/stool.,Inform your doctor immediately if you experience severe headache, vision changes, confusion, or seizures (signs of PRES).,Avoid surgery or dental procedures without notifying your oncologist; therapy may need to be paused.,Females of childbearing age must use effective contraception during and for 6 months after treatment.,Do not drive if you experience vision problems or dizziness from therapy.
Take this medication exactly as prescribed, with or without food.,Do not crush or chew extended-release formulations.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, energy drinks) as it may increase side effects.,Report symptoms such as rapid heart rate, persistent nausea/vomiting, insomnia, or seizures immediately.,Do not stop abruptly without consulting your doctor.,Keep a regular dosing schedule to maintain consistent blood levels.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVASTIN vs AMINOPHYLLIN, answered by our medical review team.
AVASTIN is a Antineoplastic (Angiogenesis Inhibitor) that works by Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.. AMINOPHYLLIN is a Xanthine Bronchodilator that works by Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVASTIN and AMINOPHYLLIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVASTIN is: 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).. The standard adult dose of AMINOPHYLLIN is: Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVASTIN and AMINOPHYLLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVASTIN is classified as Category C. Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal imp. AMINOPHYLLIN is classified as Category C. Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal ast. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.